Cohance Lifesciences Q3FY26 Revenue Declines 19.5% to ₹544.6 Crore; 9MFY26 Revenue Down 6.7%
Cohance Lifesciences reported Q3FY26 revenue of ₹544.6 crore, a 19.5% decrease. 9MFY26 revenue was ₹1,649.4 crore, down 6.7%. Gross margins improved to 72.8% for 9MFY26. Adjusted EBITDA for 9MFY26 was ₹347.7 crore, a 43% decline. The company cited customer inventory adjustments and biotech funding cycles for the performance.
The financial results show a significant decline in revenue and profitability, which could impact investor sentiment and the company's valuation. However, the company highlights improving gross margins and ongoing strategic initiatives, suggesting potential for future recovery.
The company reported a decline in revenue and adjusted EBITDA for both the quarter and nine-month period, citing external factors such as customer inventory adjustments and biotech funding cycles.
Cohance Lifesciences Limited announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results on February 12, 2026. The company reported a revenue decline of 19.5% to ₹544.6 crore for Q3FY26, with adjusted EBITDA falling by 68% to ₹84.7 crore. For the nine months ended December 31, 2025 (9MFY26), revenue declined by 6.7% to ₹1,649.4 crore. However, gross margins improved to 72.8% for 9MFY26, up approximately 200 basis points year-on-year. Adjusted EBITDA for 9MFY26 declined by 43% to ₹347.7 crore, with margins at 21.1%. The company attributed the revenue decline to customer-led inventory adjustments, delayed reloads, and moderation in select commercial products, along with biotech funding cycles impacting ADC and oligonucleotide platforms. The company also approved revisions to authorized Key Managerial Personnel for determining materiality of events and information, effective February 12, 2026. The Board meeting commenced at 3:00 PM IST and concluded at 4:15 PM IST.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.